UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 9 (B3GNT9)

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 9 (B3GNT9) is a glycosyltransferase enzyme predicted to catalyze the transfer of N-acetylglucosamine (GlcNAc) from UDP-GlcNAc to beta-galactose substrates, forming β1-3 glycosidic linkages involved in the biosynthesis of poly-N-acetyllactosamine chains and mucin-type O-linked glycosylation[4]. B3GNT9 is a type II membrane protein localized to the Golgi apparatus, predicted to participate in protein glycosylation pathways that are essential for protein folding, stability, trafficking, and cell-cell communication. The gene encodes a protein involved in the metabolism of glycoproteins and may indirectly impact disease pathways, particularly in cancer, where abnormal glycosylation is associated with tumor progression and metastasis[2][4]. B3GNT9 is part of a broader family of glycosyltransferases implicated in various disease processes, but its specific clinical roles, therapeutic targeting, and biomarker applications are not well characterized at this time.

Other names

B3GNT9UNQ1922/PRO4397BGnT-9Beta-1,3-Gn-T9Beta-1,3-N-acetylglucosaminyltransferase 9Beta3Gn-T9MGC4655beta-1,3-galactosyltransferase-related protein